Navigation Links
Cepheid Schedules Teleconference and Webcast for Third Quarter 2007 Results

SUNNYVALE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) will announce financial results for the third quarter of 2007 after the markets close on Thursday, Nov. 1, 2007. The announcement will be followed by a live conference call and webcast that afternoon at 4:30 p.m. Eastern Time.

CEO John Bishop and Senior V.P. and CFO John Sluis will host the conference call to discuss Cepheid's financial results and business highlights. Interested participants and investors may access the teleconference call by dialing 866-713-8564 (U.S./Canada) or 617-597-5312 (international), participant code 54436442. A telephonic replay will be available for seven days beginning at 6:30 p.m. Eastern Time. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 20626524.

The webcast of the call can be accessed on the Investor section of Cepheid's Web site at Web participants are encouraged to go to the Web site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. After the live webcast, a replay will remain available in the Investors section of Cepheid's Web site for 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See for more information.

SOURCE Cepheid
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Shorter Radiation Schedules Found To Be More Effective For Patients With Breast Cancer
2. Vaccination Schedules Rates among Canadian Kids Dip Low
3. UP Government Fixes Work Schedules for Provincial Medical Service Doctors
4. Third artificial heart patient introduced
5. Extra hormone found to cut appetite by a third
6. Third generation Small pox vaccine from Cell-culture
7. Surgery Offers Better Treatment For Third Degree Piles
8. One Third Of All Cancers Preventable!
9. Britain Announces Third Transfusion Related Mad Cow Case
10. Kleins Third Way Has Tough Opposition
11. Ignorance about AIDS rampart in Third of College Students: Chinese survey
Post Your Comments:
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... is actively feeding the Frederick area economy by obtaining investment capital for emerging ... the past 2½ years that have already resulted in more than a million ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: